Skip to main content

previous disabled Page of 2
and
  1. No Access

    Chapter

    Monoamin-Oxidase-Hemmer

    Die Monoamin-Oxidase (MAO, EC 1.4.2.4; Amin: Sauerstoff-Oxidoreduktase [desaminierend]) ist ein relativ unspezifisches mitochondriales Enzym. Es metabolisiert monoaminerge Neurotransmitter (wie Adrenalin, Nora...

    M. Gerlach, P. Riederer, J. R. Martin in Neuro-Psychopharmaka Ein Therapie-Handbuch (2002)

  2. No Access

    Article

    CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease

    The propargylamine derivative CGP 3466 (dibenzo[b,f]oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine) has previously been found to exhibit neurorescuing and antiapoptotic properties in several in vitro and in vivo...

    P.C. Waldmeier, W.P.J.M. Spooren in Naunyn-Schmiedeberg's Archives of Pharmaco… (2000)

  3. No Access

    Chapter and Conference Paper

    Neurorescuing effects of the GAPDH ligand CGP 3466B

    Deprenyl, used for the treatment of Parkinson’s disease, was reported to possess neurorescuing/antiapoptotic effects independent of its MAO-B inhibiting properties. It is metabolized to (-)-desmethyldeprenyl, ...

    P. C. Waldmeier, A. A. Boulton, A. R. Cools in Advances in Research on Neurodegeneration (2000)

  4. No Access

    Article

    Effect of carbamazepine, oxcarbazepine and lamotrigine on the increase in extracellular glutamate elicited by veratridine in rat cortex and striatum

    Lamotrigine, carbamazepine and oxcarbazepine inhibit veratrine-induced neurotransmitter release from rat brain slices in concentrations corresponding to those reached in plasma or brain in experimental animals...

    P. C. Waldmeier, P. Martin, K. Stöcklin in Naunyn-Schmiedeberg's Archives of Pharmaco… (1996)

  5. No Access

    Article

    Brofaromine — a review of its pharmacological properties and therapeutic use

    The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potentia...

    H. -P. Volz, C. H. Gleiter, P. C. Waldmeier, M. Struck in Journal of Neural Transmission (1996)

  6. No Access

    Article

    A role for computer simulation in solving the riddles of autoreceptor-mediated regulation of GABA release

    The autoreceptor-mediated control of GABA release was simulated on a personal computer using commercially available software (STELLATM/ITHINKTM). The experimental data to be matched were taken from previous publi...

    T. Christen, P. A. Baumann, P. C. Waldmeier in Naunyn-Schmiedeberg's Archives of Pharmaco… (1993)

  7. No Access

    Article

    Autoreceptor-mediated regulation of GABA release: role of uptake inhibition and effects of novel GABAB antagonists

    While the role of GABAB autoreceptors in the regulation of GABA release in synaptosomes and brain slices is well established, little is known about their role in vivo. Doubts have arisen because there is an appar...

    P. C. Waldmeier, Ch. Hertz, P. Wicki in Naunyn-Schmiedeberg's Archives of Pharmaco… (1993)

  8. No Access

    Article

    Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET)

    The extent and duration of striatal dopamine-D2 receptor occupancy by savoxepine in humans has been studied using positron emission tomography with [11C]-raclopride, in order to investigate why the anticipated fa...

    K. L. Leenders, A. Antonini, R. Thomann in European Journal of Clinical Pharmacology (1993)

  9. No Access

    Article

    Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum

    The effects of local and systemic administration of the potent GABA uptake inhibitor, SK&F 89976, on GABA overflow from the striatum of conscious rats were investigated in brain dialysis experiments. Administr...

    P.C. Waldmeier, K. Stöcklin in Naunyn-Schmiedeberg's Archives of Pharmaco… (1992)

  10. No Access

    Article

    Systemic administration of baclofen and the GABAB antagonist, CGP 35348, does not affect GABA, glutamate or aspartate in microdialysates of the striatum of conscious rats

    Previous in vitro experiments have shown that the GABAB agonist, baclofen, and the antagonist, CGP 35348, respectively, decrease and increase the autoreceptor-mediated release of GABA in brain slices and synaptos...

    P. C. Waldmeier, K. Stöcklin in Naunyn-Schmiedeberg's Archives of Pharmaco… (1992)

  11. No Access

    Article

    CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure

    CGP 28014 (N-(2-pyridone-6-yl)-N′,N′-di-n-propylformamidine) or its methanesulfonate salt CGP 28014 A was suspected to be a catechol-O-methyl-transferase (COMT) inhibitor because it was found to reduce the lev...

    P. C. Waldmeier, P. A. Baumann in Naunyn-Schmiedeberg's Archives of Pharmaco… (1990)

  12. No Access

    Article

    Investigations on GABAB receptor-mediated autoinhibition of GABA release

    In this study, we have investigated the effects of phaclofen on the [3H] overflow from [3H]GABA prelabelled rat cortical slices and its interaction with the effects of (−)-baclofen in dependence of the stimulatio...

    P. A. Baumann, P. Wicki, C. Stierlin in Naunyn-Schmiedeberg's Archives of Pharmaco… (1990)

  13. No Access

    Article

    Release of endogenous GABA from the substantia nigra is not controlled by GABA autoreceptors

    The characteristics of the release of GABA from slices of the rat substantia nigra, elicited by electrical stimulation at frequencies of 0.5–48 Hz and by elevated K+ concentrations ranging from 15–35 mmol/l, was ...

    P. C. Waldmeier, P. Wicki, J.-J. Feldtrauer in Naunyn-Schmiedeberg's Archives of Pharmaco… (1989)

  14. No Access

    Article

    Ca2+-dependent release of endogenous GABA from rat cortical slices from different pools by different stimulation conditions

    The previously reported inhibitory effect of (−)-baclofen on the electrically evoked release of endogenous GABA from rat brain slices indicated the possibility of existence of GABAB autoreceptors. In this study, ...

    P. C. Waldmeier, P. Wicki, J. -J. Feldtrauer in Naunyn-Schmiedeberg's Archives of Pharmaco… (1989)

  15. No Access

    Article

    The measurement of the release of endogenous GABA from rat brain slices by liquid chromatography with electrochemical detection

    A method for the determination of GABA by derivatization with 2,4,6-trinitrobenzenesulphonic acid and subsequent separation and quantitation by HPLC with electrochemical detection was characterized with respec...

    P. C. Waldmeier, P. Wicki, J. J. Feldtrauer in Naunyn-Schmiedeberg's Archives of Pharmaco… (1988)

  16. No Access

    Chapter and Conference Paper

    Basic and Clinical Aspects of the Activity of the New Monoamine Oxidase Inhibitors

    The clinical relevance of the neurobiochemical and pharmacological properties of the new generation of monoamine oxidase inhibitors (MAOIs) is reviewed and discussed. The most distinctive characteristics of th...

    A. Delini-Stula, E. Radeke, P. C. Waldmeier in Psychopharmacology: Current Trends (1988)

  17. No Access

    Book and Conference Proceedings

  18. No Access

    Chapter and Conference Paper

    Der Beitrag der Biochemie zur Psychiatrischen Forschung und Therapie

    Vorstellungen über die Materie, aus welcher das Gehirn besteht, und welchen Änderungen sie während dessen Funktion unterworfen sein könnte, gab es natürlich schon früh in der Geschichte der Menschheit, und im ...

    P. C. Waldmeier in Das Verhältnis der Psychiatrie zu ihren Nachbardisziplinen (1986)

  19. No Access

    Chapter

    Urinary Excretion of Tryptamine, MHPG, HVA, VMA, and HIAA by Volunteers treated with CGP 4718, a combined inhibitor of MAO-A and 5-HT Uptake

    The new substance CGP 4718 A (4-(5-chloro-2-benzofuranyl)-1-methylpiperidine hydrochloride) in animal experiments shows both 5-HT-uptake blocking and (preferentially) MAO-A inhibiting properties. CGP 4718 A wa...

    K. H. Antonin, E. Nilsson, P. C. Waldmeier in Neuropsychopharmacology of the Trace Amines (1985)

  20. No Access

    Chapter

    Cerebral 2-Phenylethylamine Concentrations and Turnover not Influenced by Various Pharmacological Treatments in Rats

    2-Phenylethylamine (PEA), a compound with stimulant properties when administered to animals, occurs in minute quantities in the normal mammalian brain (Durden et al. 1973). The turnover of this amine is high (...

    P. C. Waldmeier, A.-M. Buchle, J. Lauber in Neuropsychopharmacology of the Trace Amines (1985)

previous disabled Page of 2